Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
[Case Study by Xingsheng] Issue 298: A Case Presentation on Nilotinib Combined with Chemotherapy for Advanced Pancreatic Cancer
View details
→
[Case Study] Issue 297: Nilotinib Treatment in Patients with Locally Advanced Pancreatic Cancer
Biotech Pharma Named Yicheng Outstanding Innovation Enterprise of 2023
[Case Report] Issue 296: A Case Report on Nilotinib Treatment for Advanced Cervical Cancer
[Case Study] Issue 295: Nilotinib as Adjuvant Therapy for Patients with Laryngeal Malignant Tumors After Chemoradiotherapy
January 2024